When did Halozyme Therapeutics report Q4 2024 earnings?

Halozyme Therapeutics (HALO) reported Q4 2024 earnings on February 18, 2025 after market close.

What were Halozyme Therapeutics's Q4 2024 revenue and EPS?

Halozyme Therapeutics reported revenue of $298.0M and eps of $1.26 for Q4 2024.

Did Halozyme Therapeutics beat estimates in Q4 2024?

Revenue beat the consensus estimate of $285.7M by $12.3M. EPS beat the consensus estimate of $1.17 by $0.09.

Where can I find Halozyme Therapeutics's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001159036-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.

Halozyme Therapeutics HALO Q4 2024 Annual earnings

Reported February 18, 2025 · After market close

Revenue$298.0MBeat by $12.3M

EPS$1.26Beat by $0.09

Revenue estimate$285.7M

EPS estimate$1.17

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$402.3M

EPS estimate$1.82

Financials

Q4 2024

Income statement

See full

Revenue$298.0M+29.5%

Gross profit$256.0M+44.0%

Operating income$175.5M+73.7%

Net income$137.0M+60.5%

EPS (diluted)$1.06+63.1%

Balance sheet

See full

Cash & equivalents$115.9M-2.1%

Total debt$1.5B+0.3%

Total equity$363.8M+334%

Total assets$2.1B+19.1%

Cash flow

See full

Operating cash flow$178.5M+74.4%

CapEx$3.1M+17.6%

Free cash flow$175.4M+75.8%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$6.08B+27.5%

Enterprise value$7.5B+21.4%

P/E13.7×-3.2×

P/S6×+0.2×

Profitability

See full

Gross margin84.3%+7.5pp

Operating margin54.3%+13.6pp

Net margin43.7%+9.8pp

FCF margin46.1%+1.1pp

Returns & leverage

See full

Return on equity198.4%-23.7pp

Debt / equity4.2×-14.1×

Current ratio7.8×+1.2×

Segments

By product

See full

Royalties$170.4M+39.6%

Proprietary product sales$47.3M+21.1%

Sales-based milestones$30.0M—

Bulk rHuPH20 sales$19.7M-32.6%

Device partnered product sales$12.4M+9.5%

By geography

See full

All other foreign$2.4M—

Versus estimates

Revenue

Q1 2026$376.7MBeat by $18.1M Q4 2025$451.8MBeat by $16.1M Q3 2025$354.3MMiss by $92.2M Q2 2025$325.7MMiss by $5.1M Q1 2025$264.9MMiss by $16.1M

Q4 2024$298.0MBeat by $12.3M

Diluted EPS

Q1 2026$1.60Beat by $0.06 Q4 2025-$0.24Miss by $2.39 Q3 2025$1.72Beat by $0.09 Q2 2025$1.54Beat by $0.31 Q1 2025$1.11Beat by $0.16

Q4 2024$1.26Beat by $0.09

Ask the moment Halozyme Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Halozyme Therapeutics report Q4 2024 earnings?: Halozyme Therapeutics (HALO) reported Q4 2024 earnings on February 18, 2025 after market close.
What were Halozyme Therapeutics's Q4 2024 revenue and EPS?: Halozyme Therapeutics reported revenue of $298.0M and eps of $1.26 for Q4 2024.
Did Halozyme Therapeutics beat estimates in Q4 2024?: Revenue beat the consensus estimate of $285.7M by $12.3M. EPS beat the consensus estimate of $1.17 by $0.09.
Where can I find Halozyme Therapeutics's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001159036-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.